Alzheimer's Disease: Experimental, Investigational, or Unproven Treatments (CPB 0788, reviewed 2025-11-19)
Aetna considers the treatments listed in this bulletin experimental, investigational or unproven for Alzheimer's disease because their effectiveness for that indication has not been established. The list includes acupuncture, applied behavior analysis, deep brain stimulation, gene therapy, intravenous immunoglobulins, lithium, music therapy, statins, stem cell therapy, transcranial magnetic and direct current stimulation, vagus nerve stimulation, and monoclonal antibodies such as solanezumab, bapineuzumab, crenezumab and semorinemab. The CPT, HCPCS and ICD-10 codes named in the bulletin are not covered for the indications the bulletin lists, including Alzheimer's disease (ICD-10 G30.0 through G30.9).